Formic Acid

Formic Acid

SCHEMBL30206162

CNc1nc(Nc2ccc(CN3CC4(COC4)C3)cc2)c(C(N)=O)nc1-c1cncc2c1ncn2C.O=CO.O=CO

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKE Q14164 1/20 0.33
▸ TBK1 Q9UHD2 1/20 0.33
▸ CCNC P24863 2/20 0.33
▸ CDK8 P49336 2/20 0.33
▸ EML4 Q9HC35 5/20 0.32
▸ ALK Q9UM73 5/20 0.32
▸ SYK P43405 3/20 0.32
▸ TLR8 Q9NR97 1/20 0.32
▸ TLR7 Q9NYK1 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.31
▸ PDGFRA P16234 2/20 0.31
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ CDK2 P24941 2/20 0.30
▸ AURKA O14965 1/20 0.30
▸ JAK2 O60674 1/20 0.30
▸ RET P07949 2/20 0.30
▸ ROS1 P08922 2/20 0.30
▸ FLT3 P36888 2/20 0.30
▸ CCNA2 P20248 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30801879 0.97 IKBKE (0.35) IKBKETBK1CCNCCDK8EML4
SCHEMBL24944188 0.97 IKBKE (0.35) IKBKETBK1CCNCCDK8EML4
Formic Acid SCHEMBL30205591 0.93 LRRK2 (0.35) CCNCCDK8ALKTLR8TLR7
SCHEMBL24944496 0.90 LRRK2 (0.36) IKBKETBK1CCNCCDK8ALK
SCHEMBL30206172 0.90 LRRK2 (0.35) CCNCCDK8SYKTLR8TLR7
Formic Acid SCHEMBL30205666 0.89 TBK1 (0.37) IKBKETBK1CCNCCDK8EML4
Formic Acid SCHEMBL30206367 0.88 IKBKE (0.43) IKBKETBK1EML4ALKSYK
Formic Acid SCHEMBL30205548 0.87 CCNC (0.38) IKBKETBK1CCNCCDK8EML4
Formic Acid SCHEMBL29173318 0.87 CCNC (0.38) IKBKETBK1CCNCCDK8EML4
SCHEMBL24944183 0.86 SYK (0.44) CCNCCDK8EML4ALKSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 IKBKE 223/4885TBK1 1990/4885CCNC 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback